• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Director Szela Mary T was granted 8,400 shares (SEC Form 4)

    6/15/26 8:40:31 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    SEC FORM 4/ASEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Szela Mary T

    (Last)(First)(Middle)
    C/O ABSCI CORPORATION
    18105 SE MILL PLAIN BOULEVARD

    (Street)
    VANCOUVER WASHINGTON 98683

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Absci Corp [ ABSI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/04/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    06/08/2026
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock06/04/2026A8,400(1)A$08,400D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (right to buy)$7.3406/04/2026A33,200 (2)06/03/2036Common Stock33,200$033,200D
    Explanation of Responses:
    1. The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date.
    2. The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date.
    Remarks:
    This amended Form 4, as originally filed on June 8, 2026, is being filed to correct the amount of stock options and RSUs granted to the Reporting Person. This Form 4 amendment updates both equity awards to reflect 33,200 stock options and 8,400 RSUs originally granted to the Reporting Person on June 4, 2026.
    /s/ Shelby Walker, attorney-in-fact06/15/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    6/4/2026$12.00Outperform
    Leerink Partners
    5/28/2026$9.00Buy
    BTIG Research
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    10/2/2025Overweight
    Analyst
    7/3/2025$7.00Overweight
    Morgan Stanley
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    More analyst ratings

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pangalos Menelas N bought $200,748 worth of shares (37,453 units at $5.36), increasing direct ownership by 19% to 232,308 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    5/13/26 4:05:17 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Innovation Officer Busch Andreas bought $229,000 worth of shares (100,000 units at $2.29), increasing direct ownership by 31% to 421,446 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/16/26 4:17:22 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Pangalos Menelas N bought $205,760 worth of shares (75,095 units at $2.74), increasing direct ownership by 66% to 189,055 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/3/26 4:13:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

    Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at a price of $7.41 per share, before deducting underwriting discounts and commissions. The gross proceeds from the offering, bef

    6/24/26 6:35:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

    Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2027 VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with

    6/24/26 6:30:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Szela Mary T was granted 8,400 shares (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    6/15/26 8:40:31 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Mcginnis Karen K was granted 10,100 shares, increasing direct ownership by 26% to 48,420 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    6/11/26 11:28:16 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Szela Mary T was granted 10,100 shares (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    6/8/26 9:59:15 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    SEC Filings

    View All

    Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Absci Corp (0001672688) (Filer)

    6/24/26 6:32:11 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Absci Corp (0001672688) (Filer)

    6/5/26 4:08:47 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Absci Corporation

    10-Q - Absci Corp (0001672688) (Filer)

    5/7/26 4:24:29 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Absci Corporation with a new price target

    Leerink Partners initiated coverage of Absci Corporation with a rating of Outperform and set a new price target of $12.00

    6/4/26 8:44:36 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BTIG Research initiated coverage on Absci Corporation with a new price target

    BTIG Research initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

    5/28/26 8:55:01 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Corporation downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32

    1/8/26 8:35:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Financials

    Live finance-specific insights

    View All

    Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

    Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the

    5/7/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

    VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The

    4/23/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

    Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported

    3/24/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Absci Corporation

    SC 13G - Absci Corp (0001672688) (Subject)

    11/14/24 4:02:50 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Absci Corporation

    SC 13G/A - Absci Corp (0001672688) (Subject)

    11/12/24 9:50:12 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    SC 13D/A - Absci Corp (0001672688) (Subject)

    3/5/24 5:15:30 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    View All

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

    MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover

    6/12/26 9:00:00 AM ET
    $ABSI
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care